Spots Global Cancer Trial Database for recurrent verrucous carcinoma of the larynx

Every month we try and update this database with for recurrent verrucous carcinoma of the larynx cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00639769	Head and Neck C...	cisplatin irinotecan hydr...	18 Years -	Vanderbilt-Ingram Cancer Center
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors	NCT00006036	Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu...	cisplatin lurtotecan lipo...	18 Years - 120 Years	Canadian Cancer Trials Group
Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function	NCT00002901	Breast Cancer Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu...	docetaxel	18 Years -	City of Hope Medical Center
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer	NCT00470496	Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Thyro... Recurrent Verru... Recurrent Verru... Stage I Adenoid... Stage I Basal C... Stage I Esthesi... Stage I Follicu... Stage I Inverte... Stage I Lymphoe... Stage I Lymphoe... Stage I Midline... Stage I Mucoepi... Stage I Papilla... Stage I Salivar... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Verruco... Stage I Verruco... Stage II Adenoi... Stage II Basal ... Stage II Esthes... Stage II Follic... Stage II Invert... Stage II Lympho... Stage II Lympho... Stage II Midlin... Stage II Mucoep... Stage II Papill... Stage II Saliva... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Verruc... Stage II Verruc...	HPPH photodynamic th... conventional su...	18 Years -	Roswell Park Cancer Institute
NGR-TNF in Treating Patients With Advanced Solid Tumors	NCT00098943	Colorectal Canc... Head and Neck C... Kidney Cancer Unspecified Adu...	CNGRC peptide-T...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer	NCT00023959	Metastatic Squa... Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage III Adeno... Stage III Basal... Stage III Esthe... Stage III Inver... Stage III Lymph... Stage III Lymph... Stage III Midli... Stage III Mucoe... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Adenoi... Stage IV Basal ... Stage IV Esthes... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Untreated Metas...	hydroxyurea fluorouracil bevacizumab radiation thera... filgrastim laboratory biom...	18 Years -	National Cancer Institute (NCI)
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00507767	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	dasatinib pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer	NCT00482872	Head and Neck C...	gene expression... mutation analys... polymerase chai... polymorphism an... flow cytometry laboratory biom...	18 Years - 120 Years	Vanderbilt University Medical Center
Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer	NCT00963326	Head and Neck C...	laboratory biom...	15 Years -	National Cancer Institute (NCI)
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00096512	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	sorafenib tosyl... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer	NCT00470496	Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Thyro... Recurrent Verru... Recurrent Verru... Stage I Adenoid... Stage I Basal C... Stage I Esthesi... Stage I Follicu... Stage I Inverte... Stage I Lymphoe... Stage I Lymphoe... Stage I Midline... Stage I Mucoepi... Stage I Papilla... Stage I Salivar... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Verruco... Stage I Verruco... Stage II Adenoi... Stage II Basal ... Stage II Esthes... Stage II Follic... Stage II Invert... Stage II Lympho... Stage II Lympho... Stage II Midlin... Stage II Mucoep... Stage II Papill... Stage II Saliva... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Verruc... Stage II Verruc...	HPPH photodynamic th... conventional su...	18 Years -	Roswell Park Cancer Institute
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)	NCT00031681	Advanced Adult ... Carcinoma of th... Estrogen Recept... Extensive Stage... Gastrointestina... HER2-negative B... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Progesterone Re... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Borde... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Endom... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Border... Stage IV Breast... Stage IV Colon ... Stage IV Endome... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Triple-negative... Unresectable Ex... Unresectable Ga... Unspecified Adu... Untreated Metas...	7-hydroxystauro... irinotecan hydr... diagnostic labo...	18 Years -	National Cancer Institute (NCI)
Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function	NCT00002901	Breast Cancer Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu...	docetaxel	18 Years -	City of Hope Medical Center
Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function	NCT00002901	Breast Cancer Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu...	docetaxel	18 Years -	City of Hope Medical Center
Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer	NCT00963326	Head and Neck C...	laboratory biom...	15 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT02035527	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Oral ... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	sorafenib tosyl... cisplatin docetaxel Correlative Stu...	18 Years -	Ohio State University Comprehensive Cancer Center
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	NCT00041171	Adult Solid Tum... Breast Cancer Head and Neck C... Kidney and Urin... Male Reproducti... Thorax and Resp...	Hypericum perfo... docetaxel placebo	18 Years - 120 Years	Alliance for Clinical Trials in Oncology
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors	NCT00089362	Male Breast Can... Recurrent Adeno... Recurrent Basal... Recurrent Breas... Recurrent Colon... Recurrent Esthe... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Melan... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage III Adeno... Stage III Basal... Stage III Colon... Stage III Esthe... Stage III Gastr... Stage III Inver... Stage III Lymph... Stage III Lymph... Stage III Melan... Stage III Midli... Stage III Mucoe... Stage III Ovari... Stage III Renal... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IIIB Brea... Stage IIIC Brea... Stage IV Adenoi... Stage IV Basal ... Stage IV Breast... Stage IV Colon ... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Melano... Stage IV Midlin... Stage IV Mucoep... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Unspecified Adu... Untreated Metas...	alvespimycin hy... laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer	NCT00897793	Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Prostate Cancer	venipuncture radiation thera...	18 Years -	Vanderbilt-Ingram Cancer Center
Docetaxel in Treating Patients With Solid Tumors	NCT00003565	Bladder Cancer Breast Cancer Head and Neck C... Lung Cancer Unspecified Adu...	docetaxel	18 Years -	Alliance for Clinical Trials in Oncology
Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer	NCT00898742	Head and Neck C...	DNA and tissue ... reverse transcr... mass spectromet...	-	Vanderbilt-Ingram Cancer Center
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery	NCT00738868	Head and Neck C...	cetuximab stereotactic bo...	18 Years -	National Cancer Institute (NCI)
Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy	NCT01728480	Mucositis Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Squamo... Stage IV Squamo... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	entolimod intensity-modul... cisplatin pharmacological... laboratory biom...	18 Years -	Roswell Park Cancer Institute
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00507767	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	dasatinib pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy	NCT02123511	Mucositis Oral Complicati... Recurrent Adeno... Recurrent Basal... Recurrent Lymph... Recurrent Lymph... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage I Adenoid... Stage I Basal C... Stage I Lymphoe... Stage I Lymphoe... Stage I Mucoepi... Stage I Salivar... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Verruco... Stage I Verruco... Stage II Adenoi... Stage II Basal ... Stage II Lympho... Stage II Lympho... Stage II Mucoep... Stage II Saliva... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Verruc... Stage II Verruc... Stage III Adeno... Stage III Basal... Stage III Lymph... Stage III Lymph... Stage III Mucoe... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Lympho... Stage IV Squamo... Stage IVA Adeno... Stage IVA Basal... Stage IVA Lymph... Stage IVA Mucoe... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Adeno... Stage IVB Basal... Stage IVB Lymph... Stage IVB Mucoe... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Adeno... Stage IVC Basal... Stage IVC Lymph... Stage IVC Mucoe... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	acetylcysteine placebo quality-of-life... questionnaire a...	18 Years -	Mayo Clinic
Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00639769	Head and Neck C...	cisplatin irinotecan hydr...	18 Years -	Vanderbilt-Ingram Cancer Center
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy	NCT01156142	Head and Neck C... Mucositis Oral Complicati... Pain	doxepin hydroch... placebo	18 Years -	Alliance for Clinical Trials in Oncology
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery	NCT00738868	Head and Neck C...	cetuximab stereotactic bo...	18 Years -	National Cancer Institute (NCI)
Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer	NCT01313390	Head and Neck C...	docetaxel everolimus laboratory biom... pharmacological...	18 Years -	University College, London
GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer	NCT00293462	Head and Neck C... Mucositis Oral Radiation Toxic... Tongue Cancer	sargramostim oral salt and s...	18 Years -	University of California, San Francisco
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	NCT00114283	Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	lapatinib ditos... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer	NCT00482872	Head and Neck C...	gene expression... mutation analys... polymerase chai... polymorphism an... flow cytometry laboratory biom...	18 Years - 120 Years	Vanderbilt University Medical Center
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors	NCT00006036	Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu...	cisplatin lurtotecan lipo...	18 Years - 120 Years	Canadian Cancer Trials Group
L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer	NCT01155609	Mucositis Oral Complicati... Oral Complicati... Recurrent Adeno... Recurrent Basal... Recurrent Lymph... Recurrent Lymph... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage I Adenoid... Stage I Basal C... Stage I Lymphoe... Stage I Lymphoe... Stage I Mucoepi... Stage I Salivar... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Verruco... Stage I Verruco... Stage II Adenoi... Stage II Basal ... Stage II Lympho... Stage II Lympho... Stage II Mucoep... Stage II Saliva... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Verruc... Stage II Verruc... Stage III Adeno... Stage III Basal... Stage III Lymph... Stage III Lymph... Stage III Mucoe... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Adenoi... Stage IV Basal ... Stage IV Lympho... Stage IV Lympho... Stage IV Mucoep... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc...	quality-of-life... management of t... L-lysine	18 Years -	University of Washington
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab	NCT00939627	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	cetuximab placebo sorafenib tosyl... laboratory biom... quality-of-life...	18 Years -	National Cancer Institute (NCI)
Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck	NCT00906360	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Tongue Cancer Untreated Metas...	sunitinib malat... pharmacological... 3-dimensional c... cetuximab	18 Years -	National Cancer Institute (NCI)
GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer	NCT00293462	Head and Neck C... Mucositis Oral Radiation Toxic... Tongue Cancer	sargramostim oral salt and s...	18 Years -	University of California, San Francisco
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer	NCT00397384	Adenocarcinoma ... Adenocarcinoma ... Advanced Adult ... Carcinoma of th... Gastrointestina... Metastatic Gast... Metastatic Squa... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Colon... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Pancr... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Colon ... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Pancre... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Tongue Cancer Unresectable Ex... Unresectable Ga...	cetuximab erlotinib hydro... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer	NCT00004901	Head and Neck C...	ethynyluracil fluorouracil hydroxyurea radiation thera...	18 Years -	National Cancer Institute (NCI)
Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer	NCT00509665	Head and Neck C...	doxorubicin hyd... gemcitabine hyd...	18 Years - 120 Years	Medical University of South Carolina
Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer	NCT00448552	Head and Neck C...	capecitabine oxaliplatin	18 Years - 120 Years	University of Miami
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer	NCT00573989	Head and Neck C...	erlotinib hydro... pemetrexed diso... quality-of-life... intensity-modul...	18 Years - 120 Years	Wake Forest University Health Sciences
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer	NCT00068497	Anaplastic Thyr... Insular Thyroid... Metastatic Para... Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Parat... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Thyro... Recurrent Verru... Stage III Folli... Stage III Papil... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Verru... Stage IIIB Non-... Stage IV Lympho... Stage IV Non-sm... Stage IV Squamo... Stage IV Squamo... Stage IVA Adeno... Stage IVA Basal... Stage IVA Esthe... Stage IVA Folli... Stage IVA Inver... Stage IVA Lymph... Stage IVA Midli... Stage IVA Mucoe... Stage IVA Papil... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Adeno... Stage IVB Basal... Stage IVB Esthe... Stage IVB Folli... Stage IVB Inver... Stage IVB Lymph... Stage IVB Midli... Stage IVB Mucoe... Stage IVB Papil... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Adeno... Stage IVC Basal... Stage IVC Esthe... Stage IVC Folli... Stage IVC Inver... Stage IVC Lymph... Stage IVC Midli... Stage IVC Mucoe... Stage IVC Papil... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Thryoid Gland N... Thyroid Gland M... Tongue Cancer Untreated Metas...	gefitinib	-	National Cancer Institute (NCI)
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors	NCT00019331	Colorectal Canc... Endometrial Can... Head and Neck C... Liver Cancer Lung Cancer Melanoma (Skin) Pancreatic Canc... Testicular Germ... Unspecified Adu...	aldesleukin ras peptide can... sargramostim DetoxPC	18 Years -	National Cancer Institute (NCI)
Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy	NCT01728480	Mucositis Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Squamo... Stage IV Squamo... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	entolimod intensity-modul... cisplatin pharmacological... laboratory biom...	18 Years -	Roswell Park Cancer Institute
Insomnia in Patients Undergoing Chemotherapy and Radiation Therapy for Head and Neck Cancer	NCT00616590	Fatigue Head and Neck C... Psychosocial Ef... Sleep Disorders	medical chart r... questionnaire a... fatigue assessm... quality-of-life...	21 Years -	Vanderbilt University
Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer	NCT00898300	Head and Neck C...	biologic sample... biopsy	18 Years -	Radiation Therapy Oncology Group
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)	NCT00031681	Advanced Adult ... Carcinoma of th... Estrogen Recept... Extensive Stage... Gastrointestina... HER2-negative B... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Progesterone Re... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Borde... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Endom... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Border... Stage IV Breast... Stage IV Colon ... Stage IV Endome... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Triple-negative... Unresectable Ex... Unresectable Ga... Unspecified Adu... Untreated Metas...	7-hydroxystauro... irinotecan hydr... diagnostic labo...	18 Years -	National Cancer Institute (NCI)
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer	NCT00017511	Head and Neck C... Oral Complicati... Radiation Toxic...	cevimeline hydr...	18 Years -	Daiichi Sankyo
Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer	NCT01313390	Head and Neck C...	docetaxel everolimus laboratory biom... pharmacological...	18 Years -	University College, London
Family Quality of Life Among Families With a Member Who is a Cancer Patient	NCT00544336	Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Prostate Cancer Solid Tumor	questionnaire a... survey administ... quality-of-life...	21 Years -	Vanderbilt-Ingram Cancer Center
Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer	NCT00090337	Head and Neck C... Pain	acupuncture the... standard follow...	-	Memorial Sloan Kettering Cancer Center
NGR-TNF in Treating Patients With Advanced Solid Tumors	NCT00098943	Colorectal Canc... Head and Neck C... Kidney Cancer Unspecified Adu...	CNGRC peptide-T...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer	NCT00573989	Head and Neck C...	erlotinib hydro... pemetrexed diso... quality-of-life... intensity-modul...	18 Years - 120 Years	Wake Forest University Health Sciences
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor	NCT01096381	Breast Cancer Cardiovascular ... Colorectal Canc... Fallopian Tube ... Head and Neck C... Lung Cancer Ovarian Cancer Peritoneal Cavi... Unspecified Adu...	laboratory biom... questionnaire a...	18 Years -	Vanderbilt-Ingram Cancer Center
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor	NCT01096381	Breast Cancer Cardiovascular ... Colorectal Canc... Fallopian Tube ... Head and Neck C... Lung Cancer Ovarian Cancer Peritoneal Cavi... Unspecified Adu...	laboratory biom... questionnaire a...	18 Years -	Vanderbilt-Ingram Cancer Center
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00507767	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	dasatinib pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery	NCT00738868	Head and Neck C...	cetuximab stereotactic bo...	18 Years -	National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck	NCT00033618	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	ixabepilone laboratory biom...	18 Years -	National Cancer Institute (NCI)
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection	NCT01249443	HIV Infection Recurrent Anal ... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Recurrent Metas... Recurrent Non-s... Recurrent Ovari... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Anal C... Stage IV Breast... Stage IV Esopha... Stage IV Gastri... Stage IV Non-sm... Stage IV Ovaria... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Unspecified Adu...	vorinostat diagnostic labo... pharmacological... carboplatin paclitaxel	18 Years -	AIDS Malignancy Consortium
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)	NCT00031681	Advanced Adult ... Carcinoma of th... Estrogen Recept... Extensive Stage... Gastrointestina... HER2-negative B... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Progesterone Re... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Borde... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Endom... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Border... Stage IV Breast... Stage IV Colon ... Stage IV Endome... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Triple-negative... Unresectable Ex... Unresectable Ga... Unspecified Adu... Untreated Metas...	7-hydroxystauro... irinotecan hydr... diagnostic labo...	18 Years -	National Cancer Institute (NCI)
Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia	NCT00503776	Dysphagia Head and Neck C... Mucositis Xerostomia	exercise interv... amifostine trih... therapeutic die...	21 Years -	Vanderbilt-Ingram Cancer Center
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer	NCT01316757	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Tongue Cancer Untreated Metas...	cetuximab paclitaxel carboplatin erlotinib hydro... laboratory biom...	18 Years -	Fox Chase Cancer Center
Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer	NCT00090337	Head and Neck C... Pain	acupuncture the... standard follow...	-	Memorial Sloan Kettering Cancer Center
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer	NCT01847326	Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Tongue Cancer	carboplatin paclitaxel albu... fluorouracil hydroxyurea therapeutic con... radiation thera... hyperfractionat... laboratory biom...	18 Years -	University of Chicago
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors	NCT00089362	Male Breast Can... Recurrent Adeno... Recurrent Basal... Recurrent Breas... Recurrent Colon... Recurrent Esthe... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Melan... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage III Adeno... Stage III Basal... Stage III Colon... Stage III Esthe... Stage III Gastr... Stage III Inver... Stage III Lymph... Stage III Lymph... Stage III Melan... Stage III Midli... Stage III Mucoe... Stage III Ovari... Stage III Renal... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IIIB Brea... Stage IIIC Brea... Stage IV Adenoi... Stage IV Basal ... Stage IV Breast... Stage IV Colon ... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Melano... Stage IV Midlin... Stage IV Mucoep... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Unspecified Adu... Untreated Metas...	alvespimycin hy... laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00095628	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Saliv... Stage IVA Squam... Stage IVB Saliv... Stage IVB Squam... Stage IVC Saliv... Stage IVC Squam...	ispinesib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck	NCT00005647	Head and Neck C...	paclitaxel semaxanib	18 Years -	Case Comprehensive Cancer Center
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer	NCT00068497	Anaplastic Thyr... Insular Thyroid... Metastatic Para... Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Parat... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Thyro... Recurrent Verru... Stage III Folli... Stage III Papil... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Verru... Stage IIIB Non-... Stage IV Lympho... Stage IV Non-sm... Stage IV Squamo... Stage IV Squamo... Stage IVA Adeno... Stage IVA Basal... Stage IVA Esthe... Stage IVA Folli... Stage IVA Inver... Stage IVA Lymph... Stage IVA Midli... Stage IVA Mucoe... Stage IVA Papil... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Adeno... Stage IVB Basal... Stage IVB Esthe... Stage IVB Folli... Stage IVB Inver... Stage IVB Lymph... Stage IVB Midli... Stage IVB Mucoe... Stage IVB Papil... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Adeno... Stage IVC Basal... Stage IVC Esthe... Stage IVC Folli... Stage IVC Inver... Stage IVC Lymph... Stage IVC Midli... Stage IVC Mucoe... Stage IVC Papil... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Thryoid Gland N... Thyroid Gland M... Tongue Cancer Untreated Metas...	gefitinib	-	National Cancer Institute (NCI)
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck	NCT01473784	Recurrent Adeno... Recurrent Mucoe... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage 0 Hypopha... Stage 0 Larynge... Stage 0 Lip and... Stage I Adenoid... Stage I Mucoepi... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Verruco... Stage I Verruco... Stage II Adenoi... Stage II Mucoep... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Verruc... Stage II Verruc... Stage III Adeno... Stage III Mucoe... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Squamo... Stage IVA Adeno... Stage IVA Mucoe... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Adeno... Stage IVB Mucoe... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Adeno... Stage IVC Mucoe... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	transoral robot... quality of life...	18 Years -	Ohio State University Comprehensive Cancer Center
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction	NCT00030498	Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Brain Ste... Adult Diffuse A... Adult Ependymob... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Mixed Gli... Adult Myxopapil... Adult Oligodend... Adult Pilocytic... Adult Primary H... Adult Subependy... Advanced Adult ... Advanced Malign... Male Breast Can... Recurrent Adeno... Recurrent Adult... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Esoph... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Malig... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage II Esopha... Stage II Pancre... Stage III Esoph... Stage III Pancr... Stage IIIB Non-... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Bladde... Stage IV Breast... Stage IV Colon ... Stage IV Esopha... Stage IV Esthes... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Unspecified Adu... Untreated Metas...	erlotinib hydro... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer	NCT00004065	Bladder Cancer Breast Cancer Colorectal Canc... Gastric Cancer Head and Neck C... Kidney Cancer Leukemia Lung Cancer Melanoma (Skin) Ovarian Cancer Prostate Cancer Unspecified Adu...	tanespimycin	18 Years -	Memorial Sloan Kettering Cancer Center
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor	NCT00021047	Esophageal Canc... Extrahepatic Bi... Gastric Cancer Head and Neck C... Liver Cancer Unspecified Adu...	capecitabine carboplatin epirubicin hydr...	18 Years -	National Institutes of Health Clinical Center (CC)
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer	NCT00022217	Head and Neck C...	carboplatin cisplatin-e the... paclitaxel	18 Years -	National Cancer Institute (NCI)
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck	NCT01334177	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Saliva... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	TLR8 agonist VT... cetuximab laboratory biom... pharmacogenomic...	18 Years -	University of Washington
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants	NCT00898638	Head and Neck C...	biologic sample... medical chart r...	18 Years -	Vanderbilt University Medical Center
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT00103259	Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Tongue Cancer	bortezomib irinotecan hydr... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab	NCT00939627	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	cetuximab placebo sorafenib tosyl... laboratory biom... quality-of-life...	18 Years -	National Cancer Institute (NCI)
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer	NCT01316757	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Tongue Cancer Untreated Metas...	cetuximab paclitaxel carboplatin erlotinib hydro... laboratory biom...	18 Years -	Fox Chase Cancer Center
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer	NCT00492089	Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Brain Ste... Adult Central N... Adult Choroid P... Adult Diffuse A... Adult Ependymom... Adult Grade II ... Adult Grade III... Adult Malignant... Adult Mixed Gli... Adult Oligodend... Adult Papillary... Adult Pineocyto... Malignant Neopl... Meningeal Melan... Radiation Toxic... Recurrent Adeno... Recurrent Adult... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Midli... Recurrent Mucoe... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage I Adenoid... Stage I Basal C... Stage I Esthesi... Stage I Inverte... Stage I Lymphoe... Stage I Lymphoe... Stage I Midline... Stage I Mucoepi... Stage I Salivar... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Verruco... Stage I Verruco... Stage III Adeno... Stage III Basal... Stage III Esthe... Stage III Inver... Stage III Lymph... Stage III Midli... Stage III Mucoe... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Adenoi... Stage IV Basal ... Stage IV Esthes... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc...	bevacizumab placebo magnetic resona... quality-of-life...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: